Histotype
Myeloma
.png)
| Parameter | Information |
|---|---|
| Strain | SCID Beige |
| Implant Type | Cells |
| Implant Location | IV |
| Time to Staging | 14 days |
| Time to Evaluation Size (days) | 32.6 days |
| Td | 2.1 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Human
Ref #
3254
Spotlight on MM.1S: A model for multiple myeloma
Learn more about this cell line in our scientific spotlights:
Multiple myeloma is a clonal B cell malignancy characterized by the accumulation of terminally differentiated, antibody-producing plasma cells in the bone marrow. Genetic mutations within the myeloma cells and their interaction with various cytokines and growth factors contribute to the invasiveness of the disease and enhanced drug resistance. Patients are generally asymptomatic until very late state disease. Once disease is detected, localization in the bones, especially the spine, is common. Currently, the gold standard therapy is a combination of doxorubicin and dexamethasone with bortezomib. The addition of bortezomib improves the overall response rate close to 50%.1